Tue, April 5, 2022
Mon, April 4, 2022
Sun, April 3, 2022
Fri, April 1, 2022
Thu, March 31, 2022
Wed, March 30, 2022
Tue, March 29, 2022
Mon, March 28, 2022
Sun, March 27, 2022
Fri, March 25, 2022

Marc Goodman Maintained (AMLX) at Buy with Decreased Target to $31 on, Mar 31st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-31-on-mar-31st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Marc Goodman of SVB Leerink, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Buy with Decreased Target from $50 to $31 on, Mar 31st, 2022.

Marc has made no other calls on AMLX in the last 4 months.



There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 0 agree with Marc's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Marc


  • Umer Raffat of "Evercore ISI Group" Initiated at Buy on, Wednesday, February 2nd, 2022
  • Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Tuesday, February 1st, 2022
  • Chris Shibutani of "Goldman Sachs" Initiated at Strong Buy and Held Target at $36 on, Tuesday, February 1st, 2022

Publication Contributing Sources